Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06447116 · ClinicalTrials.gov registry record · NA

An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke

A NA study of Acute Ischemic Stroke, sponsored by Jacobs institute.

Active
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT06447116 is a NA study of Acute Ischemic Stroke that is active but no longer recruiting, run by Jacobs institute. The registered enrollment target is 15 participants, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06447116, a NA study of Acute Ischemic Stroke, is active but no longer recruiting, sponsored by Jacobs institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The Jacobs Institute is conducting a Sponsor Investigator study of patients ≥ 18 years to establish safety and preliminary effectiveness in treating extracranial stenosis with the CGuard Prime™ Carotid Stent in the setting as an acute ischemic stroke.

Conditions Studied

Interventions

  • DEVICE CGuard Prime™ Carotid Stent System

Study Locations (1)

New York

  • Jacobs Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-01-01
Est. Completion 2026-12-31
Phase NA

Sponsor

Jacobs institute

5 total trials

What the Registry Record Tells You About NCT06447116

The ClinicalTrials.gov registry entry for NCT06447116 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (96% lower). The listed sponsor is Jacobs institute, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which CGuard Prime™ Carotid Stent System is the first listed.

NCT06447116 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06447116 about?

NCT06447116 is a clinical study titled "An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke". The Jacobs Institute is conducting a Sponsor Investigator study of patients ≥ 18 years to establish safety and preliminary effectiveness in treating extracranial stenosis with the CGuard Prime™ Carotid Stent in the setting as an acute ischemic stroke.

What is the current status of trial NCT06447116?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-01-01. Estimated completion is 2026-12-31.

What conditions does trial NCT06447116 study?

This clinical trial studies the following conditions: Acute Ischemic Stroke.

What interventions are being tested in trial NCT06447116?

The interventions under investigation include: CGuard Prime™ Carotid Stent System (DEVICE).

Who is sponsoring clinical trial NCT06447116?

This trial is sponsored by Jacobs institute, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06447116 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.